A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

An Open-Label Study to Determine the Pharmacokinetics of a Single Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode for Which Acute Treatment With a Benzodiazepine is Clinically Indicated

The purpose of this study is to determine the pharmacokinetics of Diazepam Nasal Spray following a single dose in epileptic patients experiencing a seizure episode.

Inclusion Criteria:

• Provide signed informed consent for study participation.
• General good health with no clinically significant unstable abnormalities.
• Diagnosis of epilepsy.

Exclusion Criteria:

• Individuals receiving warfarin (Coumadin®) or dabigatran (Pradaxa®).
• Use of any investigational drug within 30 days.
• Blood or plasma donation within 30 days.
• Not willing or unable to tolerate blood draws.